Earlier this month, Merck and Daiichi Sankyo announced that ifinatamab deruxtecan was granted Breakthrough Therapy Designation by the U.S. FDA for treating adult patients with extensive-stage small ...

Merck's ifinatamab deruxtecan wins FDA Breakthrough Therapy status for treating adults with extensive-stage small cell lung ...

Merck & Co (NYSE: MRK) and Daiichi Sankyo (TYO: 4568) have received Breakthrough Therapy designation from the US regulator ...

Investors in the region are awaiting India's HSBC Composite flash purchasing managers' index reading for August expected ...

Rahway: Merck and Daiichi Sankyo have announced that Ifinatamab deruxtecan (I-DXd) has been granted Breakthrough Therapy ...

Developed by Daiichi Sankyo and Merck, it treats patients with Pretreated Extensive-Stage Small Cell Lung Cancer.

The Delhi High Court recently clarified that it does not have the power to directly attach immovable properties situated outside its territorial jurisdiction even for enforcement of foreign arbitral ...

Daiichi Sankyo Co. shares dropped the most in three months following a series of discounted block trades in the Japanese pharmaceutical company.

In November 2019, Daiichi Sankyo filed a Declaratory Judgment action in the District Court of Delaware against Seagen in response to communications from Seagen claiming certain intellectual ...

On December 23, 2020, Daiichi Sankyo filed a petition with the U.S. Patent Office for post-grant review contesting the patentability of certain claims within the ’039 patent. About Daiichi Sankyo ...